Anacardic acid attenuates pressure-overload cardiac hypertrophy through inhibiting histone acetylases

Area of Science:

• Cardiovascular Biology
• Epigenetics
• Pharmacology

Background:

• Cardiac hypertrophy is a precursor to heart failure, necessitating novel therapeutic strategies.
• Histone acetylation plays a critical role in cardiac remodeling and hypertrophy.
• Current treatments for cardiac hypertrophy have suboptimal efficacy.

Purpose of the Study:

• To investigate the potential of anacardic acid (AA) in attenuating cardiac hypertrophy.
• To explore the underlying mechanisms of AA's effects, focusing on histone acetylation modulation.
• To assess AA's impact on cardiac function and survival in a mouse model.

Main Methods:

• Utilized a transverse aortic constriction (TAC) mouse model to induce cardiac hypertrophy.
• Administered anacardic acid (AA) to TAC mice.
• Assessed histone acetylation levels (H3K9ac), expression of histone acetyltransferases (p300, PCAF), and transcription factor activity (MEF2A).
• Quantified expression of cardiac hypertrophy-linked genes (ANP, β-MHC) and evaluated cardiac function and survival rates.

Main Results:

• AA treatment attenuated histone H3 lysine 9 acetylation (H3K9ac) by inhibiting p300 and PCAF expression in TAC mice.
• AA normalized the transcriptional activity of the heart nuclear transcription factor MEF2A.
• AA reversed the upregulation of cardiac hypertrophy markers (ANP, β-MHC), improved cardiac function, and increased survival rates in TAC mice.

Conclusions:

• Anacardic acid (AA) effectively attenuates cardiac hypertrophy in a TAC mouse model.
• AA exerts its cardioprotective effects by modulating histone acetylation, specifically inhibiting p300 and PCAF, and normalizing MEF2A activity.
• These findings highlight AA as a promising therapeutic agent for preventing and treating hypertrophic cardiomyopathy.